Malignant gliomas are aggressive tumors that often progress despite multimodality therapy. At recurrence, treatment approaches must balance the potential morbidity of a given therapy against the survival benefit that might be achieved. A new study reports that irradiation in this setting is well tolerated and could prolong survival.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Circular RNA PRKCI promotes glioma cell progression by inhibiting microRNA-545
Cell Death & Disease Open Access 13 August 2019
-
ROS-p53-cyclophilin-D signaling mediates salinomycin-induced glioma cell necrosis
Journal of Experimental & Clinical Cancer Research Open Access 30 May 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fogh, S. E. et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J. Clin. Oncol. 28, 3048–3053 (2010).
Larson, D. A. et al. Gamma knife for glioma: selection factors and survival. Int. J. Radiat. Oncol. Biol. Phys. 36, 1045–1053 (1996).
Kondziolka, D., Flickinger, J. C., Bissonette, D. J., Bozik, M. & Lunsford, L. D. Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. Neurosurgery 41, 776–783 (1997).
Bernstein, M. et al. Brachytherapy for recurrent malignant astrocytoma. Int. J. Radiat. Oncol. Biol. Phys. 30, 1213–1217 (1994).
Gabayan, A. J. et al. GliaSite brachtherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Neurosurgery 58, 701–709 (2006).
Shepherd, S. F. et al. Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int. J. Radiat. Oncol. Biol. Phys. 37, 393–398 (1997).
Fokas, E. et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas. Strahlenther. Onkol. 185, 235–240 (2009).
Combs, S. E., Thilman, C., Edler, L., Debus, J. & Schulz-Ertner, D. Efficacy of fractionated stereotactic re-irradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J. Clin. Oncol. 23, 8863–8869 (2005).
Grosu, A. L. et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 63, 511–519 (2005).
Wen, P. Y. et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol. 28, 1963–1972 (2010).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Pollack, I. Therapeutic benefits of reirradiation for recurrent brain tumors. Nat Rev Neurol 6, 533–535 (2010). https://doi.org/10.1038/nrneurol.2010.144
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2010.144
This article is cited by
-
Circular RNA PRKCI promotes glioma cell progression by inhibiting microRNA-545
Cell Death & Disease (2019)
-
microRNA-200a downregulation in human glioma leads to Gαi1 over-expression, Akt activation, and cell proliferation
Oncogene (2018)
-
ROS-p53-cyclophilin-D signaling mediates salinomycin-induced glioma cell necrosis
Journal of Experimental & Clinical Cancer Research (2015)
